中成药治疗原发性失眠的疗效与安全性:109项随机试验的网络荟萃分析
与安慰剂和苯二氮䓬类药物相比,疏肝解郁胶囊、参芪五味子片、天梦口服液/胶囊联合苯二氮䓬类药物可显著改善睡眠质量;参芪五味子片和安神补脑液/颗粒可延长主观总睡眠时间并缩短入睡潜伏期。所有中成药在胃肠道和头晕事件方面与西药或安慰剂相比差异不显著或风险更低,但证据质量评为低或极低。
要点
- 疏肝解郁胶囊、参芪五味子片、天梦口服液/胶囊联合苯二氮䓬类可显著改善睡眠质量
- 参芪五味子片和安神补脑液/颗粒可延长主观总睡眠时间并缩短入睡潜伏期
- 中成药胃肠道和头晕事件风险不高于西药或安慰剂,但证据质量低或极低
核心结论
- 中成药治疗原发性失眠显示出疗效与安全性,疏肝解郁胶囊、参芪五味子片和天梦口服液等显示潜在获益。
- 当前结论基于低质量试验,需设计严谨、采用患者重要结局的试验验证。
研究设计与样本
- 系统检索8个数据库自建库至2022年7月,纳入比较中成药或中成药联合西药与另一种中成药或西药/安慰剂的成人原发性失眠RCT。
- 采用CINeMA框架评估证据确定性。
主要发现
- 与安慰剂和苯二氮䓬类药物相比,疏肝解郁胶囊、参芪五味子片、天梦口服液/胶囊联合苯二氮䓬类药物显著改善睡眠质量。
- 与苯二氮䓬类药物相比,参芪五味子片和安神补脑液/颗粒显著延长主观总睡眠时间并缩短入睡潜伏期。
- 所有中成药在胃肠道和头晕事件方面与西药或安慰剂相比差异不显著或风险更低。
- 证据确定性评为低或极低。
关键数值与推荐
- 纳入109项RCT,11,488例患者,女性占54.26%,中位年龄47.97岁。
临床怎么用
- 临床可考虑将疏肝解郁胶囊、参芪五味子片、天梦口服液/胶囊(联合苯二氮䓬类)用于改善原发性失眠患者睡眠质量。
- 参芪五味子片和安神补脑液/颗粒可用于延长主观总睡眠时间并缩短入睡潜伏期。
- 选用中成药时需结合低或极低证据质量的现状,谨慎解读疗效结论。
局限性
- 纳入试验质量较低,证据确定性评为低或极低。
- 结论需设计严谨、采用患者重要结局的试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Chinese patent medicine (CPM) is formulated using Chinese herbal medicines as raw materials according to prescribed methods and preparation processes. It is one of the most commonly used complementary and alternative therapies for insomnia in China. Dozens of CPMs have been applied in clinical settings to treat primary insomnia, and ample evidence has proven the efficacy and safety of various CPMs. AIM OF THE STUDY: We aimed to use the network meta-analysis method to simultaneously compare the efficacy and safety of Chinese patent medicines for primary insomnia. MATERIALS AND METHODS: We systematically searched eight databases from their inception to July 2022. The relevant randomized controlled trials (RCTs) were eligible if they compared one CPM or one CPM plus a Western drug with another CPM or with Western drug/placebo in adults with primary insomnia. Two reviewers independently performed literature screening, data extraction, and risk of bias assessment. We evaluated the certainty of evidence utilizing CINeMA (Confidence in Network Meta-Analysis) framework. RESULTS: A total of 109 RCTs involved 11,488 patients (54.26% female) with a median age of 47.97 years. Forty-five CPMs were assessed in this study. Compared with placebo and Benzodiazepine drugs, Shugan Jieyu capsules, Shenqi Wuweizi tablets, and Tianmeng oral liquid/capsules combined with Benzodiazepine drugs significantly improved sleep quality. Compared to Benzodiazepine drugs, both Shenqi Wuweizi tablets and Anshen Bunao liquid/granules significantly prolonged subjective total sleep duration and reduced sleep onset latency. Considering safety, all CPMs showed an insignificant difference or lower risk of gastrointestinal and dizziness events compared to Western drugs or placebo. The certainty of evidences was rated as low or very low. CONCLUSION: This meta-analysis demonstrated the efficacy and safety of CPMs for primary insomnia, especially several CPMs such as Shugan Jieyu capsules, Shenqi Wuweizi tablets and Tianmeng oral liquid, which have shown their potential benefits. However, the present conclusions are based on low quality trials. Well-designed trials, including rigorous methods and patient-important outcomes, are required to verify these results.
引用
- Ma N, Pan B, Yang S, et al. Comparative efficacy and safety of Chinese patent medicines for primary insomnia: A systematic review and network meta-analysis of 109 randomized trials. J Ethnopharmacol. 2024. PMID: 39701221. doi:10.1016/j.jep.2024.119254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。